Reply to the Editor  by McKneally, Martin
low-up and has rehabilitated himself by
performing social work within the prison
walls. This case persuaded me to research
the law and resulted in a publication in the
Journal of Indian Law Institute.2 The sub-
ject was capital punishment and medical
science.
In the case referred to in the editorial, it
appears that medical professionals and le-
gal professionals can come together and
seek an alternative where valuable human
resource is not wasted in the hope of retri-
bution. I am referring to the large number
of prisoners waiting a death sentence in US
prisons. They could be potential organ do-
nors for the community. With the assis-
tance of the medical profession, each pris-
oner who is to be executed can provide
organs for 8 to 10 patients.
This would certainly appeal to society
at large. The article published in the Jour-
nal of Indian Law Institute2 has interested
the law commission in India, which is con-
sidering this suggestion. However, capital
punishment itself is rarely given out in In-
dian courts. Perhaps this thought may be
worth a closer look in your community,
where the number of convicts on death row
is large.
A. Sampath Kumar, MCh
Department of Cardiothoracic/Vascular
Surgery
All India Institute of Medical Sciences
New Delhi, India
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Reply to the Editor:
Readers will be grateful for the informative
letter from Dr Sampath Kumar, who raises
two interesting themes for ethical analysis.
The case that he reports shows how
changes in contextual details can clarify
values and illuminate moral reasoning de-
veloped from analysis of an index case, like
our heart transplant patient. This approach
to ethics is referred to as casuistry. In his
case, the patient was not just in prison but
was on death row, intensifying the apparent
strength of the argument from justice to
withhold treatment because of the serious-
ness of the crime. The treatment was an
expensive valve operation, although it did
not consume as scarce and as valuable a
resource as a donor heart. The principle
that guided his decision was that prisoners
are our fellow citizens and fellow human
beings, to whom physicians have a fidu-
ciary duty to provide care within the
boundaries of resource availability. It is
enriching that he can give us the outcome,
underlining the appropriateness of his de-
cision to apply this principle.
The second theme that he raises is the
issue of allowing prisoners to be organ
donors. The voluntary or involuntary re-
moval of vital organs after execution in
China is an efficient but potentially abusive
solution to the donor shortage. Clifford
Bartz, a federal inmate in Pennsylvania,
described the Inmate Organ Donor Net-
work in the March issue of the Kennedy
Institute of Ethics Journal.1 Bartz and his
colleagues propose that qualified inmates
who pledge up to three organs on their
death should be given 1 year of suspended
prison time, and those who serve as living
donors should receive 7 years of reduced
time. He describes several voluntary dona-
tions of organs from prisoners to their
needy relatives. These are examples of a
form of trade, trading time for organs. In
my Minnesota case of the prisoner who
wanted to collect “rent” for his donated
kidney, described in my reply to Dr Richen-
bacher’s letter,2 this proved to be a Faus-
tian bargain, but this single example should
not lead to a categorical ban. I recommend
a more empirical approach to test the opti-
mistic hypothesis that under the best cir-
cumstances, prisoner organ donation can
be an act of heroism leading to trust and
rehabilitation of a fallen comrade on the
road of life.
We need rewards for donation. As a
blood donor, I favor some advantage
within the health care system for those who
enrich it by donation. This might parallel
the airlines’ policy of rewarding frequent
flyers for their loyalty with expedited
boarding and free air travel on some under-
filled flights. Blood donors, and particu-
larly organ donors, deserve reasonable re-
wards within the health care system, as
long as they do not unfairly disadvantage
other patients. Such a reward system would
strengthen the value assigned by society to
the act or intention to donate.3 Finally, the
use of financial rewards should be explored
as even Veatch,4 a longtime opponent of
this policy, has grouchily come to accept.
The Council on Ethical and Judicial Affairs
of the American Medical Association,
stimulated no doubt by Bob Sade’s pres-
ence on the council, has recommended that
an empirical trial of financial rewards for
organ donors should be conducted to deter-
mine whether it will favorably or unfavor-
ably affect the overall rate of donation or
reduce the donor pool.5
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Bivalirudin as alternative to both
danaparoid and heparin in off-pump
coronary artery bypass grafting
To the Editor:
I enjoyed the recent article “Heparin Ver-
sus Danaparoid in Off-Pump Coronary By-
pass Grafting: Results of a Prospective
Randomized Clinical Trial” by Carrier and
colleagues.1 I favor off-pump coronary ar-
tery bypass grafting in patients with hepa-
rin-induced thrombocytopenia (HIT). Did
Carrier and colleagues1 consider using a
short-acting thrombin inhibitor such as
bivalirudin (Angiomax) rather than danap-
aroid as the heparin alternative?
I have used bivalirudin,2 a short-acting
thrombin inhibitor, in several patients with
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